Skip to main content
. Author manuscript; available in PMC: 2024 Feb 13.
Published in final edited form as: Cancer Cell. 2023 Jan 12;41(2):304–322.e7. doi: 10.1016/j.ccell.2022.12.008

Figure 7: Oncometabolic reprogramming drives cancer hyperprogression during immunotherapy.

Figure 7:

Mechanistic scheme of HPD development. IFNγ produced by ICB-activated T cells targets tumor FGF2 signaling, inducing PKM2 phosphorylation at Y105 and decreasing NAD+ levels, thereby diminishing SIRT1 activity and lessening β-catenin deacetylation. Consequently, β-catenin signaling pathway is activated resulting in enhanced oncogenic potential and HPD.